Recent developments in drug-eluting stents

Journal of Molecular Medicine

Volumn 89, Issue 6, 2011, Pages 545-553

  Li, Yue ^a   Bhindi, Ravinay ^b   Khachigian, Levon M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Bioabsorbable stents; Cardiology; Cardiovascular; Drug Delivery; Drug eluting stents; Late thrombosis; Polymer; Restenosis

Indexed keywords

EVEROLIMUS; PACLITAXEL; RAPAMYCIN; UMIROLIMUS; ZOTAROLIMUS;

BARE METAL STENT; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; REVIEW; STENT THROMBOSIS;

ANGIOPLASTY, BALLOON, CORONARY; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; PACLITAXEL; POLYMERS; SIROLIMUS; THROMBOSIS; TREATMENT OUTCOME;

EID: 79959998747     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-011-0729-3     Document Type: Review

References (79)

1. G Erez E Leitersdorf 2007 The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease Eur J Vasc Endovasc Surg 33 2 192 201 17185010 10.1016/j.ejvs.2006.11.020 1:STN:280: DC%2BD2s%2FjslGiug%3D%3D (Pubitemid 46090501)
2. Glaudemans, A.W., et al., (2010) Molecular imaging in atherosclerosis. Eur J Nucl Med Mol Imaging 37(12):2381-2397
3. EJ Topol, et al. 1993 A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl J Med 329 4 221 227 8316266 10.1056/NEJM199307223290401 1:STN:280:DyaK3szgt1yitg%3D%3D (Pubitemid 23203812)
4. AG Adelman, et al. 1993 A comparison of directional atherectomy with balloon angioplasty for lesions of the left anterior descending coronary artery N Engl J Med 329 4 228 233 8316267 10.1056/NEJM199307223290402 1:STN:280:DyaK3szgt1yitw%3D%3D (Pubitemid 23203813)
5. PW Serruys, et al. 1994 A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331 8 489 495 8041413 10.1056/ NEJM199408253310801 1:STN:280:DyaK2czhs1anuw%3D%3D (Pubitemid 24256751)
6. DL Fischman, et al. 1994 A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331 8 496 501 8041414 10.1056/NEJM199408253310802 1:STN:280:DyaK2czhs1amsg%3D%3D (Pubitemid 24256752)
7. BARI-Investigators 1996 Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators N Engl J Med 335 4 217 225 10.1056/NEJM199607253350401 (Pubitemid 26249569)
8. P Agostoni, et al. 2006 Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era Am Heart J 151 3 682 689 16504632 10.1016/j.ahj.2005.05.001 1:CAS:528: DC%2BD28XhvVWmsbs%3D (Pubitemid 43290261)
9. ED Grech 2003 ABC of interventional cardiology: percutaneous coronary intervention. I: history and development BMJ 326 7398 1080 1082 12750213 10.1136/bmj.326.7398.1080 (Pubitemid 36629730)
10. A Caixeta, et al. 2009 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents J Am Coll Cardiol 54 10 894 902 19712798 10.1016/j.jacc.2009.04.077
11. SK James, et al. 2009 Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden N Engl J Med 360 19 1933 1945 19420363 10.1056/NEJMoa0809902 1:CAS:528:DC%2BD1MXlsFCqtL4%3D
12. MC Morice, et al. 2007 Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial J Am Coll Cardiol 50 14 1299 1304 17903626 10.1016/j.jacc.2007.06.029 1:CAS:528:DC%2BD2sXhtFSlurfF (Pubitemid 47454687)
13. S Silber, et al. 2009 Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions Circulation 120 15 1498 1504 19786634 10.1161/CIRCULATIONAHA.109.849877 1:CAS:528:DC%2BD1MXht1Wmsr%2FK
14. G Weisz, et al. 2009 Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial J Am Coll Cardiol 53 17 1488 1497 19389558 10.1016/j.jacc.2009.01.050 1:CAS:528:DC%2BD1MXltVCns74%3D
15. E Grube, et al. 2009 TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions EuroIntervention 4 5 572 577 19378676 10.4244/EIJV4I5A97
16. S Silber 2005 Cypher versus taxus: are there differences? J Interv Cardiol 18 6 441 446 16336424 10.1111/j.1540-8183.2005.00084.x (Pubitemid 41726993)
17. AM Galloe, et al. 2008 Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial JAMA 299 4 409 416 18230778 10.1001/jama.299.4.409 1:CAS:528:DC%2BD1cXhtl2ntLg%3D (Pubitemid 351185949)
18. C Simsek, et al. 2010 The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries JACC: Cardiovascular Interventions 3 10 1051 1058 20965464 10.1016/j.jcin.2010.08.003
19. C Stettler, et al. 2007 Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis Lancet 370 9591 937 948 17869634 10.1016/S0140-6736(07)61444-5 1:CAS:528:DC%2BD2sXhtVeqsL7E (Pubitemid 47393576)
20. GW Stone, et al. 2007 Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 10 998 1008 17296824 10.1056/NEJMoa067193 1:CAS:528:DC%2BD2sXisFKmu7o%3D (Pubitemid 46376800)
21. A Kastrati, et al. 2007 Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 356 10 1030 1039 17296823 10.1056/NEJMoa067484 1:CAS:528:DC%2BD2sXisFOjurY%3D (Pubitemid 46376803)
22. AJ Kirtane, et al. 2009 Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies Circulation 119 25 3198 3206 19528338 10.1161/CIRCULATIONAHA.108.826479 1:CAS:528:DC%2BD1MXnsFyiurc%3D
23. E Camenzind PG Steg W Wijns 2007 Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern Circulation 115 11 1440 1455 17344324 10.1161/CIRCULATIONAHA.106.666800 discussion 1455
24. P Wenaweser, et al. 2008 Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study J Am Coll Cardiol 52 14 1134 1140 18804739 10.1016/j.jacc.2008.07.006 1:CAS:528:DC%2BD1cXhtFersr7J
25. LO Jensen, et al. 2007 Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions J Am Coll Cardiol 50 5 463 470 17662400 10.1016/j.jacc.2007.06.002 1:CAS:528: DC%2BD2sXot1ymt7g%3D (Pubitemid 47088133)
26. RA Byrne, et al. 2009 Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment Drug Saf 32 9 749 770 19670915 10.2165/11316500-000000000-00000 1:CAS:528:DC%2BD1MXht1WhsbvF
27. N Kukreja Y Onuma PW Serruys 2009 Xience V everolimus-eluting coronary stent Expert Rev Med Devices 6 3 219 229 19419279 10.1586/erd.09.1 1:CAS:528:DC%2BD1MXlsFCntbY%3D
28. PW Serruys, et al. 2009 Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease N Engl J Med 360 10 961 972 19228612 10.1056/NEJMoa0804626 1:CAS:528:DC%2BD1MXislOlsLo%3D
29. FG Kushner, et al. 2009 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 22 2271 2306 19923169 10.1161/CIRCULATIONAHA.109.192663
30. CL Grines, et al. 2007 Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians Catheter Cardiovasc Interv 69 3 334 340 17295287 10.1002/ccd.21124 (Pubitemid 46339272)
31. AV Finn, et al. 2007 Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 18 2435 2441 17438147 10.1161/CIRCULATIONAHA.107.693739 (Pubitemid 46717966)
32. A Farb, et al. 2003 Pathological mechanisms of fatal late coronary stent thrombosis in humans Circulation 108 14 1701 1706 14504181 10.1161/01.CIR. 0000091115.05480.B0 (Pubitemid 37243657)
33. M Joner, et al. 2006 Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 1 193 202 16814667 10.1016/j.jacc.2006.03.042 (Pubitemid 43929240)
34. R Iijima, et al. 2007 Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era Am Heart J 154 4 688 693 17892992 10.1016/j.ahj.2007.06.005 1:CAS:528:DC%2BD2sXhtVOit7vO (Pubitemid 47440084)
35. B Lagerqvist, et al. 2007 Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden N Engl J Med 356 10 1009 1019 17296822 10.1056/NEJMoa067722 1:CAS:528:DC%2BD2sXisFKrsLY%3D (Pubitemid 46376801)
36. S Cook, et al. 2009 Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis Circulation 120 5 391 399 19620501 10.1161/CIRCULATIONAHA.109.854398
37. RA Byrne, et al. 2009 Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer JACC: Cardiovascular Interventions 2 4 291 299 19463439 10.1016/j.jcin.2008.11.015
38. R Wessely A Kastrati A Schomig 2005 Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent Ann Intern Med 143 5 392 394 16106033 (Pubitemid 41266615)
39. W Schmidt, et al. 2009 A comparison of the mechanical performance characteristics of seven drug-eluting stent systems Catheter Cardiovasc Interv 73 3 350 360 19085917 10.1002/ccd.21832 1:STN:280:DC%2BD1M7ksFagug%3D%3D
40. L Shedden K Oldroyd P Connolly 2009 Current issues in coronary stent technology Proc Inst Mech Eng H 223 5 515 524 19623905 1:STN:280: DC%2BD1MrgtFOhtg%3D%3D
41. G Nakazawa, et al. 2009 A review of current devices and a look at new technology: drug-eluting stents Expert Rev Med Devices 6 1 33 42 19105778 10.1586/17434440.6.1.33 1:CAS:528:DC%2BD1cXhsFCjsbvI
42. A Kastrati, et al. 2001 Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial Circulation 103 23 2816 2821 11401938 1:STN:280:DC%2BD3MzjsVSksQ%3D%3D (Pubitemid 32550070)
43. J Pache, et al. 2003 Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial J Am Coll Cardiol 41 8 1283 1288 12706922 10.1016/S0735-1097(03)00119-0 (Pubitemid 36438988)
44. W Bocksch, et al. 2010 Clinical safety and efficacy of a novel thin-strut cobalt-chromium coronary stent system: results of the real world Coroflex Blue Registry Catheter Cardiovasc Interv 75 78 85 19739262
45. MA Beijk JJ Piek 2007 XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent Expert Rev Med Devices 4 1 11 21 17187467 10.1586/17434440.4.1.11 1:CAS:528:DC%2BD2sXhvFyltL4%3D (Pubitemid 46157678)
46. LM Khachigian 2000 Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function J Clin Invest 106 10 1189 1195 11086018 10.1172/JCI11620 1:CAS:528:DC%2BD3cXotlChurs%3D
47. LM Khachigian, et al. 2002 c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury: inhibition by a novel DNAzyme targeting c-Jun J Biol Chem 277 22985 22991 11891228 10.1074/jbc.M200977200 1:CAS:528:DC%2BD38XltVGrs7s%3D (Pubitemid 34967284)
48. M Murrell L Khachigian MR Ward 2007 The role of c-jun in PDTC-sensitive flow-dependent restenosis after angioplasty and stenting Atherosclerosis 194 364 371 17194461 10.1016/j.atherosclerosis.2006.11.016 1:CAS:528:DC%2BD2sXhtFerurjO (Pubitemid 47513103)
49. HC Lowe, et al. 2001 Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis Circ Res 89 670 677 11597989 10.1161/hh2001.097867 1:CAS:528:DC%2BD3MXnsF2ktbs%3D (Pubitemid 34627066)
50. FS Santiago, et al. 2007 Yin Yang-1 inhibits intimal thickening by repressing p21WAF1/Cip1 transcription and p21WAF1/Cip1-Cdk4-Cyclin D1 assembly Circ Res 101 146 155 17556661 10.1161/CIRCRESAHA.106.145235 1:CAS:528: DC%2BD2sXns1Cmsbs%3D (Pubitemid 47196582)
51. EP McFadden, et al. 2004 Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy Lancet 364 9444 1519 1521 15500897 10.1016/S0140-6736(04)17275-9 1:CAS:528:DC%2BD2cXovVKrtrs%3D (Pubitemid 39410418)
52. I Iakovou, et al. 2005 Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 17 2126 2130 15870416 10.1001/jama.293.17.2126 1:CAS:528:DC%2BD2MXjvFKiu7w%3D (Pubitemid 40617065)
53. CH Lee, et al. 2006 Late angiographic stent thrombosis of polymer based paclitaxel eluting stent Heart 92 4 551 553 16537782 10.1136/hrt.2005.073619 1:STN:280:DC%2BD287kvVClsw%3D%3D
54. J Mehilli, et al. 2008 Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis Eur Heart J 29 16 1975 1982 18550554 10.1093/eurheartj/ehn253 1:CAS:528: DC%2BD1cXhtFajtr7O
55. WJ van der Giessen, et al. 1996 Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries Circulation 94 7 1690 1697 8840862
56. JE Sousa, et al. 2001 Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study Circulation 103 2 192 195 11208675 1:CAS:528:DC%2BD3MXhtFajsLY%3D (Pubitemid 32095401)
57. G Guagliumi, et al. 2003 Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings Circulation 107 9 1340 1341 12628958 10.1161/01.CIR. 0000062700.42060.6F (Pubitemid 36314421)
58. R Virmani, et al. 2004 Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109 6 701 705 14744976 10.1161/01.CIR.0000116202.41966.D4 (Pubitemid 38222887)
59. JR Nebeker, et al. 2006 Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project J Am Coll Cardiol 47 1 175 181 16386683 10.1016/j.jacc.2005.07.071 (Pubitemid 43005183)
60. R Virmani, et al. 2002 Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans Circulation 106 21 2649 2651 12438288 10.1161/01.CIR.0000041632.02514.14 1:CAS:528:DC%2BD38XosFCrsrg%3D (Pubitemid 35364917)
61. S Commandeur HM van Beusekom WJ van der Giessen 2006 Polymers, drug release, and drug-eluting stents J Interv Cardiol 19 6 500 506 17107364 10.1111/j.1540-8183.2006.00198.x (Pubitemid 44722241)
62. MB Leon, et al. 2010 A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial J Am Coll Cardiol 55 6 543 554 20152559 10.1016/j.jacc.2009.08.067 1:CAS:528: DC%2BC3cXjt1Gnu7c%3D
63. MB Leon, et al. 2010 Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in Patients With De Novo Coronary Lesions 3-Year Follow-Up From the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) Trial JACC: Cardiovascular Interventions 3 10 1043 1050 20965463 10.1016/j.jcin.2010.07.008
64. GW Stone, et al. 2009 Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial Circulation 119 5 680 686 19171853 10.1161/CIRCULATIONAHA.108.803528 1:CAS:528:DC%2BD1MXht1Gmur0%3D
65. GW Stone, et al. 2010 Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 18 1663 1674 20445180 10.1056/NEJMoa0910496 1:CAS:528:DC%2BC3cXls1Omurg%3D
66. E Kedhi, et al. 2010 Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 9710 201 209 20060578 10.1016/S0140-6736(09)62127-9 1:CAS:528:DC%2BC3cXntVWkug%3D%3D
67. PW Serruys, et al. 2010 Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2 136 146 20554978 10.1056/NEJMoa1004130 1:CAS:528:DC%2BC3cXptFWmtrc%3D
68. M Joner, et al. 2008 Endothelial cell recovery between comparator polymer-based drug-eluting stents J Am Coll Cardiol 52 5 333 342 18652940 10.1016/j.jacc.2008.04.030 1:CAS:528:DC%2BD1cXovFyqsb8%3D (Pubitemid 352001347)
69. M Awata, et al. 2008 Angioscopic comparison of neointimal coverage between zotarolimus- and sirolimus-eluting stents J Am Coll Cardiol 52 9 789 790 18718430 10.1016/j.jacc.2008.07.007 1:CAS:528:DC%2BD1cXhtVarsLbI
70. MC John, et al. 2008 Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents JACC: Cardiovascular Interventions 1 5 535 544 19463356 10.1016/j.jcin.2008.08.004
71. N Swanson, et al. 2007 Two-year clinical results of a polymer-free, paclitaxel-eluting stent: the ELUTES trial EuroIntervention 3 1 109 112 19737693
72. S Windecker, et al. 2008 Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 9644 1163 1173 18765162 10.1016/S0140-6736(08)61244-1 1:CAS:528:DC%2BD1cXhtFOgtLvN
73. P Barlis, et al. 2010 An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study Eur Heart J 31 165 176 19889649 10.1093/eurheartj/ehp480 1:CAS:528:DC%2BC3cXntlKksQ%3D%3D
74. RA Byrne, et al. 2009 Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results Heart 95 18 1489 1494 19592388 10.1136/hrt.2009.172379 1:CAS:528:DC%2BD1MXhtlSjtrnI
75. RA Byrne, et al. 2009 Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial Eur Heart J 30 20 2441 2449 19720642 10.1093/eurheartj/ehp352
76. J Kotani, et al. 2006 Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings J Am Coll Cardiol 47 10 2108 2111 16697331 10.1016/j.jacc.2005.11.092 1:CAS:528:DC%2BD28XksFalsbk%3D
77. PW Serruys, et al. 2009 A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods Lancet 373 9667 897 910 19286089 10.1016/S0140-6736(09)60325-1 1:CAS:528:DC%2BD1MXjtFKqtro%3D
78. JA Ormiston, et al. 2008 A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial Lancet 371 9616 899 907 18342684 10.1016/S0140-6736(08)60415-8 1:CAS:528:DC%2BD1cXjtlSrt70%3D (Pubitemid 351384734)
79. A Colombo AS Sharp 2009 The bioabsorbable stent as a virtual prosthesis Lancet 373 9667 869 870 19286066 10.1016/S0140-6736(09)60521-3